This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Are Options Traders Betting on a Big Move in INSP Stock?
by Zacks Equity Research
Investors need to pay close attention to Inspire Medical Systems stock based on the movements in the options market lately.
INSPNegative Net Change
medical
FONAR Stock Gains Post Y/Y Decline in Q1 Earnings and Profit
by Zacks Equity Research
FONR reports top-line growth for first-quarter fiscal 2026 amid earnings decline and increased SG&A and operating expenses.
FONRNegative Net Change
earnings medical medical-devices
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
TEVANegative Net Change ANIPNegative Net Change AMRXPositive Net Change VTRSNegative Net Change
biotechs medical
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
by Zacks Equity Research
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
GSKNegative Net Change ALKSNegative Net Change GILDNegative Net Change FOLDPositive Net Change
biotechnology biotechs medical pharmaceuticals
HealthEquity Rolls Out Agentic AI to Elevate Member Support Experience
by Zacks Equity Research
HQY's new agentic AI is likely to provide faster, more intuitive support across channels, aiming to boost member satisfaction.
BSXNegative Net Change ISRGNegative Net Change HQYPositive Net Change MEDPNegative Net Change
medical medical-devices
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
by Aparajita Dutta
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
BMYNegative Net Change JNJPositive Net Change PFENegative Net Change MRKNegative Net Change LLYPositive Net Change ABBVPositive Net Change PJPPositive Net Change IHEPositive Net Change XPHPositive Net Change PPHNegative Net Change FTXHNegative Net Change
earnings etfs medical
TEM Continues to Strengthen Its Genomics Leadership With New Products
by Sridatri Sarkar
Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.
EXASNegative Net Change VSTMNegative Net Change GHPositive Net Change TEMPositive Net Change
medical
Forget the Fed, Bet on These 4 Stocks With Increasing Cash Flows
by Moumita C. Chattopadhyay
Four rising cash-flow stocks, including PRM, TILE, CSTL and GLDD, stand out with upgraded earnings estimates and strong VGM scores.
GLDDNegative Net Change TILENegative Net Change CSTLNegative Net Change PRMNegative Net Change
construction industrial-products medical
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
ANIPNegative Net Change ADMANegative Net Change KODPositive Net Change ARQTPositive Net Change
biotechnology biotechs earnings medical
Boston Scientific Up 7% in a Month: How Should You Play the Stock?
by Moumi Mondal
BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.
ABTPositive Net Change BSXNegative Net Change BAXNegative Net Change
medical medical-devices
New Strong Buy Stocks for November 14th
by Zacks Equity Research
NPSNY, SUZ, EVCM, LMAT and TER have been added to the Zacks Rank #1 (Strong Buy) List on Nov.14, 2025
TERPositive Net Change LMATNegative Net Change NPSNYNegative Net Change SUZNegative Net Change EVCMNegative Net Change
computers consumer-discretionary medical
BDX Unveils Portable PureWick System for On-the-Go Incontinence Care
by Zacks Equity Research
BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.
BSXNegative Net Change BDXNo Net Change HQYPositive Net Change SOLVPositive Net Change
medical medical-devices
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
by Zacks Equity Research
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
BSXNegative Net Change STXSNegative Net Change HQYPositive Net Change SOLVPositive Net Change
medical medical-devices
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
BMYNegative Net Change ALKSNegative Net Change FOLDPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat
by Zacks Equity Research
ENSG shares slip 2.2% despite Q3 earnings and revenues topping estimates, as higher service and rent costs weigh on results.
UHSNegative Net Change EXASNegative Net Change ENSGPositive Net Change VCYTNegative Net Change
earnings medical
Implied Volatility Surging for Akebia Therapeutics Stock Options
by Zacks Equity Research
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
AKBANegative Net Change
medical
IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?
by Kanishka Das
Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
AZNPositive Net Change IRWDNegative Net Change ABBVPositive Net Change
medical
The Zacks Analyst Blog Highlights Apple, Procter & Gamble and UnitedHealth
by Zacks Equity Research
Zacks spotlights Apple, Procter & Gamble, and UnitedHealth as analysts assess growth outlooks, margin pressures, and evolving catalysts across sectors.
AAPLNegative Net Change UNHNegative Net Change PGNegative Net Change
computers consumer-staples medical
The Zacks Analyst Blog Highlights Southern Copper, HCA Healthcare, General Motors, Morgan Stanley and Capital One Financial
by Zacks Equity Research
Five non-tech powerhouses Southern Copper, HCA Healthcare, General Motors, Morgan Stanley, and Capital One are Zacks' top-ranked picks to drive portfolio gains in 2026.
MSNegative Net Change COFNegative Net Change GMNegative Net Change SCCONegative Net Change HCANegative Net Change
auto-tires-trucks finance industrial-products medical
Best Momentum Stocks to Buy for Nov. 13
by Zacks Equity Research
FLEX, PODD and PRAA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Nov. 13, 2025.
PRAAPositive Net Change FLEXPositive Net Change PODDPositive Net Change
medical
Stock Market News for Nov 13, 2025
by Zacks Equity Research
Wall Street closed mixed on Wednesday, pulled up by healthcare and financial stocks.
GSNegative Net Change ABBVPositive Net Change
finance medical
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
NVSNegative Net Change ANIPNegative Net Change ADMANegative Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy, Hold or Sell CGC Stock Post Q2 Earnings Release?
by Sundeep Ganoria
Canopy Growth's narrower loss, rising Canadian sales and improving margins signal progress in its turnaround, even as competition and global headwinds persist.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical
Is Force Feedback the Next Big Catalyst for ISRG's da Vinci Sales?
by Indrajit Bandyopadhyay
Intuitive Surgical's new force-feedback upgrades for da Vinci 5 could spark its next adoption wave as early clinical evidence strengthens.
SYKNegative Net Change ISRGNegative Net Change GMEDPositive Net Change
medical medical-devices